6.47
-0.36(-5.27%)
Currency In USD
Address
One Main Street
Cambridge, MA 02142
United States of America
Phone
617 410 4650
Sector
Healthcare
Industry
Medical - Pharmaceuticals
Employees
111
First IPO Date
January 08, 2021
Name | Title | Pay | Year Born |
Mr. Nadim Ahmed | President, Chief Executive Officer & Director | 1.17M | 1968 |
Ms. Mary Kay Fenton CPA | Chief Financial Officer | 544,153 | 1964 |
Dr. Patrick A. Baeuerle Ph.D. | Co-Founder, Chief Scientific Advisor & Chairman of Scientific Advisory Board | 763,734 | 1958 |
Dr. Jeffrey Jones M.B.A., M.D., M.P.H. | Chief Medical Officer | 844,826 | 1971 |
Mr. Kevin A. Johnston | Chief Technical Operations Officer | 0 | N/A |
Mr. Steve Andre | Chief Human Resources Officer | 0 | N/A |
Ms. Rose Weldon | Senior Vice President of Corporate Affairs | 0 | N/A |
Ms. Jacquelyn L. Sumer J.D. | Chief Legal Officer, Chief Compliance Officer & Corporate Secretary | 0 | 1978 |
Dr. Corinne Savill Ph.D. | Chief Business Officer | 0 | 1959 |
Dr. Jennifer Michaelson Ph.D. | Chief Scientific Officer | 0 | 1967 |
Cullinan Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the developing of oncology and immuno-oncology therapies. Its pipeline includes CLN-978, CLN-619, Zipalertinib CLN-081/TAS6417, CLN-049, and CLN-617. The company was founded by Patrick A. Baeuerle on September 15, 2016 and is headquartered in Cambridge, MA.